Humira Biosimilar Market, By Product Type (Biosimilar Humira (Adalimumab), and Interchangeable Biosimilar Humira), By Indication (Rheumatoid Arthritis, Psoriasis, Crohn\'s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis,

Humira Biosimilar Market, By Product Type (Biosimilar Humira (Adalimumab), and Interchangeable Biosimilar Humira), By Indication (Rheumatoid Arthritis, Psoriasis, Crohn\'s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, and Other Autoimmune Conditions), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Patient Age (Adult Patients, Pediatric Patients, and Geriatric Patients), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global humira biosimilar market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Global Humira Biosimilar Market Detailed Segmentation:

• By Product Type:
• Biosimilar Humira (Adalimumab)
• Interchangeable Biosimilar Humira
• By Indication:
• Rheumatoid Arthritis
• Psoriasis
• Crohn's Disease
• Ulcerative Colitis
• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Other Autoimmune Conditions
• By Patient Age:
• Adult Patients
• Pediatric Patients
• Geriatric Patients
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• Top companies in Global Humira Biosimilar Market
• Amgen
• Samsung Bioepis Co., Ltd.
• Sandoz International GmbH (Novartis AG)
• Mylan N.V.
• Boehringer Ingelheim International GmbH
• Pfizer Inc.
• Fresenius Kabi AG
• Coherus BioSciences, Inc.
• Biogen Inc.
• AbbVie Inc.
• Celltrion Inc.
• Rani Therapeutics Holdings, Inc.
• Teva Pharmaceutical Industries Ltd
• Merck & Co., Inc.
• Viatris Inc.
• Alvotech